Savara Inc (SVRA)

$4.89

-0.18

(-3.55%)

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Savara Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 81.1% return, outperforming this stock by 29.9%

Performance

  • $4.85
    $5.11
    $4.89
    downward going graph

    0.92%

    Downside

    Day's Volatility :5.19%

    Upside

    4.31%

    downward going graph
  • $3.01
    $5.70
    $4.89
    downward going graph

    38.45%

    Downside

    52 Weeks Volatility :47.19%

    Upside

    14.21%

    downward going graph

Returns

PeriodSavara IncIndex (Russel 2000)
3 Months
-2.98%
0.0%
6 Months
14.79%
0.0%
1 Year
51.16%
0.0%
3 Years
223.84%
-21.0%

Highlights

Market Capitalization
796.7M
Book Value
$0.88
Earnings Per Share (EPS)
-0.37
PEG Ratio
0.0
Wall Street Target Price
10.71
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-30.22%
Return On Equity TTM
-58.59%
Revenue TTM
1000.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-29.0M
EBITDA
-69.4M
Diluted Eps TTM
-0.37
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.42
EPS Estimate Next Year
-0.41
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.1

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Savara Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 119.02%

Current $4.89
Target $10.71

Technicals Summary

Sell

Neutral

Buy

Savara Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Savara Inc
Savara Inc
20.44%
14.79%
51.16%
223.84%
223.84%
Moderna, Inc.
Moderna, Inc.
-16.37%
18.89%
-4.07%
-48.35%
748.18%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.16%
17.36%
52.58%
90.65%
268.9%
Novo Nordisk A/s
Novo Nordisk A/s
-0.29%
33.6%
81.13%
227.9%
496.35%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.03%
11.71%
40.03%
146.43%
177.11%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Savara Inc
Savara Inc
NA
NA
0.0
-0.42
-0.59
-0.3
NA
0.88
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Savara Inc
Savara Inc
Buy
$796.7M
223.84%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
748.18%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
268.9%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
496.35%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
177.11%
31.94
39.46%

Institutional Holdings

  • NEA Management Company, LLC

    17.71%
  • Bain Capital Life Sciences Investors, LLC

    10.54%
  • TCG Crossover Management, LLC

    7.24%
  • Jennison Associates LLC

    6.40%
  • Adage Capital Partners Gp LLC

    6.00%
  • BlackRock Inc

    5.24%

Company Information

savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com

Organization
Savara Inc
Employees
37
CEO
Mr. Matthew Pauls J.D., M.B.A.
Industry
Health Technology

FAQs